Moneycontrol PRO
LAMF
LAMF
Jump to
  • Do not require capex for next 3-4 years: Granules India

  • Portuguese Regulator clears Granules India's Gagillapur plant

  • Granules India to file 2 ANDAs in US, 4 here this year

  • Orange ibuprofen will help strengthen US portfolio: Granules

  • Expect revenue growth in coming quarters: Granules India

  • Expect 15-20% revenue growth in FY17: Granules India

  • Targeting FY16 margins at 20%: Granules India

  • Ibuprofen to add USD 2-4 mn to revenue: Granules India

  • See 20% revenue growth in FY16: Granules India

  • Eye FDA approval for new plant; rev growth at 26%: Granules

  • Will reap benefits of Auctus deal in 3-4 yrs: Granules

  • Granules India expects to grow at 30% in FY14

    "We have expanded significantly over the last two years, our assets are yielding right now a lot of the profit is because of growth in revenue," Granules India executive director Harsha Chigurupati said elaborating reasons for strong growth.

  • Granules India expects 30% growth in FY14

    Harsha Chigurupati, director, Granules India, says that last year the company reported a major increase in profit due to forex gains of around Rs 8 crore. This year too, the company performed better than previous year. There has been improvement in revenues and the company expects revenues to grow at 30 percent in FY14.

  • Expecting a growth rate of 40% in FY12: Granules India

    C Krishna Prasad, MD, Granules India, spoke to CNBC-TV 18 about the company's performance and what to expect in the days to come.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347